Cell Bio Human Tech Enters 1 Billion KRW Treasury Stock Acquisition Trust Agreement to Enhance Shareholder Value
Cell Bio Human Tech has entered into a 1 billion KRW trust agreement with Daishin Securities for treasury stock acquisition, aimed at enhancing shareholder value. The agreement runs from June 10, 2026 for one year, targeting approximately 182,815 shares, representing 1.96% of total outstanding shares. This acquisition will bring total treasury shares to over 13% of outstanding shares.
The company has sufficient financial capacity, with a dividendable profit limit of approximately 23 billion KRW as of the end of the previous fiscal year. The buyback is part of a broader shareholder return policy, given that some existing treasury shares are reserved for exchangeable bonds and employee bonuses.
The company also holds 961,765 treasury shares designated for exchangeable bonds issued in 2025, which will be disposed upon exercise of exchange rights. This potential dilution risk may be offset by the additional share acquisition.
[AI Summary]Cell Bio Human Tech's decision to buy back 1 billion KRW in treasury stock is a positive signal for shareholder value, representing 1.96% of outstanding shares and likely to stabilize the stock price. However, investors should monitor the dilution risk from outstanding exchangeable bonds.
KOSDAQ Filing Information
Major Report (Decision on Entering into a Trust Contract for Acquisition of Treasury Shares)